Immunohistochemistry was performed on tissue sections to detect PTEN and p-FAK expression. Samples were incubated with
anti-PTEN (mouse monoclonal, clone 6H2.1, Millipore) and
anti-p-FAK (rabbit monoclonal, clone 31H5L17, Thermo Fisher) antibodies, followed by
DAB Detection Kit (Ventana, Roche). Finally, sections were counterstained with Mayer's hematoxylin.
PTEN and p-FAK positivity was defined by the presence of membranous (p-FAK) and cytoplasmic (PTEN) staining in neoplastic cells. A semiquantitative analysis was performed to provide a score evaluation on a tissue area of a minimum of 6.87 mm
2 to a maximum of 457.75 mm
2.
Samples were categorized as: (i) score 0 when no staining was detectable; (ii) score 1 when staining of tumor cells was present in less than 10% of cells; (iii) score 2 when staining involved more than 10% of cells or when weak staining was present in nearly 50% of tumor cells; (iv) score 3 when intense membrane (p-FAK) and cytoplasmic (PTEN) staining was detected in at least 50% of tumor cells.
Cavazzoni A., La Monica S., Alfieri R., Ravelli A., Van Der Steen N., Sciarrillo R., Madeddu D., Lagrasta C.A., Quaini F., Bonelli M., Fumarola C., Cretella D., Digiacomo G., Tiseo M., Peters G.J., Ardizzoni A., Petronini P.G, & Giovannetti E. (2017). Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN. Oncotarget, 8(32), 53068-53083.